Clinical Trials Browser

Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT00111813 2015-05-21

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

Phase 1 Completed

34 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT00127101 2015-04-21

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Phase 1 Terminated

23 enrolled 13 charts

Lymphoid

Lymphoma

NCT00771472 2015-04-21

Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)

Phase 1 Completed

10 enrolled 11 charts

Lymphoid

Lymphoma

NCT00424775 2015-04-20

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Phase 1 Terminated

3 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00106626 2009-04-22

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors

Phase 1 Completed

52 enrolled 9 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Epigenetic Reprogramming in Relapse/Refractory AML

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

MIBG With Dinutuximab +/- Vorinostat

MK-0683-029

MK-0683-098

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

SAHA

Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer

MK-0683-074

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)

A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)

Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors